Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer

  1. Aguilar-Serra, J.
  2. Gimeno-Ballester, V.
  3. Pastor-Clerigues, A.
  4. Milara, J.
  5. Trigo-Vicente, C.
  6. Cortijo, J.
Zeitschrift:
Expert Review of Pharmacoeconomics and Outcomes Research

ISSN: 1744-8379,  1473-7167

Datum der Publikation: 2022

Ausgabe: 22

Nummer: 4

Seiten: 637-646

Art: Artikel

DOI: 10.1080/14737167.2022.1987220 GOOGLE SCHOLAR
Datenquelle: Scopus